Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + RT in Early-stage NK/T Cell Lymphoma
NCT05149170Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT05149170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149170.